Literature DB >> 27707979

APOE-Sensitive Cholinergic Sprouting Compensates for Hippocampal Dysfunctions Due to Reduced Entorhinal Input.

Jean-Bastien Bott1, Céline Héraud1, Brigitte Cosquer1, Karine Herbeaux1, Julien Aubert1, Maxime Sartori1, Romain Goutagny1, Chantal Mathis2.   

Abstract

Brain mechanisms compensating for cerebral lesions may mitigate the progression of chronic neurodegenerative disorders such as Alzheimer's disease (AD). Mild cognitive impairment (MCI), which often precedes AD, is characterized by neuronal loss in the entorhinal cortex (EC). This loss leads to a hippocampal disconnection syndrome that drives clinical progression. The concomitant sprouting of cholinergic terminals in the hippocampus has been proposed to compensate for reduced EC glutamatergic input. However, in absence of direct experimental evidence, the compensatory nature of the cholinergic sprouting and its putative mechanisms remain elusive. Transgenic mice expressing the human APOE4 allele, the main genetic risk factor for sporadic MCI/AD, display impaired cholinergic sprouting after EC lesion. Using these mice as a tool to manipulate cholinergic sprouting in a disease-relevant way, we showed that this sprouting was necessary and sufficient for the acute compensation of EC lesion-induced spatial memory deficit before a slower glutamatergic reinnervation took place. We also found that partial EC lesion generates abnormal hyperactivity in EC/dentate networks. Dentate hyperactivity was abolished by optogenetic stimulation of cholinergic fibers. Therefore, control of dentate hyperactivity by cholinergic sprouting may be involved in functional compensation after entorhinal lesion. Our results also suggest that dentate hyperactivity in MCI patients may be directly related to EC neuronal loss. Impaired sprouting during the MCI stage may contribute to the faster cognitive decline reported in APOE4 carriers. Beyond the amyloid contribution, the potential role of both cholinergic sprouting and dentate hyperactivity in AD symptomatogenesis should be considered in designing new therapeutic approaches. SIGNIFICANCE STATEMENT: Currently, curative treatment trials for Alzheimer's disease (AD) have failed. The endogenous ability of the brain to cope with neuronal loss probably represents one of the most promising therapeutic targets, but the underlying mechanisms are still unclear. Here, we show that the mammalian brain is able to manage several deleterious consequences of the loss of entorhinal neurons on hippocampal activity and cognitive performance through a fast cholinergic sprouting followed by a slower glutamatergic reinnervation. The cholinergic sprouting is gender dependent and highly sensitive to the genetic risk factor APOE4 Our findings highlight the specific impact of early loss of entorhinal input on hippocampal hyperactivity and cognitive deficits characterizing early stages of AD, especially in APOE4 carriers.
Copyright © 2016 the authors 0270-6474/16/3610473-15$15.00/0.

Entities:  

Keywords:  APOE4; Alzheimer's disease; cholinergic sprouting; entorhinal cortex; hippocampal disconnection; spatial memory

Mesh:

Substances:

Year:  2016        PMID: 27707979      PMCID: PMC6705585          DOI: 10.1523/JNEUROSCI.1174-16.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  63 in total

1.  Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment.

Authors:  J H Kordower; Y Chu; G T Stebbins; S T DeKosky; E J Cochran; D Bennett; E J Mufson
Journal:  Ann Neurol       Date:  2001-02       Impact factor: 10.422

Review 2.  Brain damage, sex hormones and recovery: a new role for progesterone and estrogen?

Authors:  D G Stein
Journal:  Trends Neurosci       Date:  2001-07       Impact factor: 13.837

Review 3.  Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease.

Authors:  J Poirier
Journal:  J Psychiatry Neurosci       Date:  1999-03       Impact factor: 6.186

Review 4.  Current concepts in mild cognitive impairment.

Authors:  R C Petersen; R Doody; A Kurz; R C Mohs; J C Morris; P V Rabins; K Ritchie; M Rossor; L Thal; B Winblad
Journal:  Arch Neurol       Date:  2001-12

5.  Effects of novelty and habituation on acetylcholine, GABA, and glutamate release from the frontal cortex and hippocampus of freely moving rats.

Authors:  M G Giovannini; A Rakovska; R S Benton; M Pazzagli; L Bianchi; G Pepeu
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

6.  Brain-state- and cell-type-specific firing of hippocampal interneurons in vivo.

Authors:  Thomas Klausberger; Peter J Magill; László F Márton; J David B Roberts; Philip M Cobden; György Buzsáki; Peter Somogyi
Journal:  Nature       Date:  2003-02-20       Impact factor: 49.962

7.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

Authors:  Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

8.  Stereological analysis of the reorganization of the dentate gyrus following entorhinal cortex lesion in mice.

Authors:  A L Phinney; M E Calhoun; A G Woods; T Deller; M Jucker
Journal:  Eur J Neurosci       Date:  2004-04       Impact factor: 3.386

9.  Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites.

Authors:  Robert T Fremeau; Kaiwen Kam; Tayyaba Qureshi; Juliette Johnson; David R Copenhagen; Jon Storm-Mathisen; Farrukh A Chaudhry; Roger A Nicoll; Robert H Edwards
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

10.  Signals that induce sprouting in the central nervous system: sprouting is delayed in a strain of mouse exhibiting delayed axonal degeneration.

Authors:  O Steward
Journal:  Exp Neurol       Date:  1992-12       Impact factor: 5.330

View more
  6 in total

Review 1.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

2.  Cholinergic Hypofunction in Presbycusis-Related Tinnitus With Cognitive Function Impairment: Emerging Hypotheses.

Authors:  Qingwei Ruan; Zhuowei Yu; Weibin Zhang; Jian Ruan; Chunhui Liu; Ruxin Zhang
Journal:  Front Aging Neurosci       Date:  2018-04-06       Impact factor: 5.750

3.  Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment.

Authors:  Jung-Min Pyun; Nayoung Ryoo; Young Ho Park; SangYun Kim
Journal:  Alzheimers Res Ther       Date:  2021-01-05       Impact factor: 6.982

Review 4.  Optogenetics: implications for Alzheimer's disease research and therapy.

Authors:  Parsa Mirzayi; Parnian Shobeiri; Amirali Kalantari; George Perry; Nima Rezaei
Journal:  Mol Brain       Date:  2022-02-23       Impact factor: 4.041

5.  Cholinergic receptor binding in unimpaired older adults, mild cognitive impairment, and Alzheimer's disease dementia.

Authors:  David L Sultzer; Aaron C Lim; Hailey L Gordon; Brandon C Yarns; Rebecca J Melrose
Journal:  Alzheimers Res Ther       Date:  2022-02-07       Impact factor: 8.823

Review 6.  The Neuroanatomy of the Reticular Nucleus Locus Coeruleus in Alzheimer's Disease.

Authors:  Filippo S Giorgi; Larisa Ryskalin; Riccardo Ruffoli; Francesca Biagioni; Fiona Limanaqi; Michela Ferrucci; Carla L Busceti; Ubaldo Bonuccelli; Francesco Fornai
Journal:  Front Neuroanat       Date:  2017-09-19       Impact factor: 3.856

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.